Literature DB >> 8613831

Petroclival meningiomas: surgical experience in 109 cases.

W T Couldwell1, T Fukushima, S L Giannotta, M H Weiss.   

Abstract

The surgical removal of petroclival meningiomas has historically been associated with a high incidence of morbidity and mortality. The 109 consecutive patients included in the present retrospective study represent a combined series of tumors operated on by the four authors during a period from 1980 to 1992. The series is composed of 40 men and 69 women ranging in age from 25 to 75 years (mean 51 years). Surgical approaches to tumors in this series included simple retromastoid (60 cases), combined supra- and infratentorial petrosal (22), transtemporal (primary transsigmoid retrolabyrinthine, translabyrinthine, or transcochlear (12), subtemporal (11), and frontotemporal transcavernous (eight). Gross-total removal was achieved in 75 patients (69%). Recurrence or progression of disease occurred in 14 patients (13%) over a 6.1-year mean follow-up period, and it was found within the cavernous sinus in 12 of these cases. Four recurrent cases demonstrated histological compatibility with malignant meningioma. Perioperative death occurred in four patients, and there were 56 significant complications in 35 other patients. Review of this series, with the attendant complications, has facilitated the authors' decision-making when considering the risk of gross-total removal in selected patients with asymptomatic cavernous sinus invasion or tumor adherent to the brainstem.

Entities:  

Mesh:

Year:  1996        PMID: 8613831     DOI: 10.3171/jns.1996.84.1.0020

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  68 in total

1.  Dural opening/removal for combined petrosal approach: technical note.

Authors:  Shunsuke Terasaka; Katsuyuki Asaoka; Hiroyuki Kobayashi; Taku Sugiyama; Shigeru Yamaguchi
Journal:  Skull Base       Date:  2011-03

Review 2.  Skull base surgery for benign skull base tumors.

Authors:  Ketan R Bulsara; Ossama Al-Mefty
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 3.  Linac radiosurgery as a tool in neurosurgery.

Authors:  R Deinsberger; J Tidstrand
Journal:  Neurosurg Rev       Date:  2005-02-22       Impact factor: 3.042

4.  Anatomo-radiological evaluation of lateral approaches to the skull base.

Authors:  M Ammirati; H K Kim; Y D Cho
Journal:  Skull Base Surg       Date:  1998

Review 5.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

Review 6.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

Review 7.  Modern endoscopic skull base neurosurgery.

Authors:  Rafael Martinez-Perez; Luis C Requena; Ricardo L Carrau; Daniel M Prevedello
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

8.  Anatomic comparison of anterior petrosectomy versus the expanded endoscopic endonasal approach: interest in petroclival tumors surgery.

Authors:  Timothée Jacquesson; Emile Simon; Moncef Berhouma; Emmanuel Jouanneau
Journal:  Surg Radiol Anat       Date:  2015-06-12       Impact factor: 1.246

9.  Lateral suboccipital retrosigmoid approach with tentorial incision for petroclival meningiomas: technical note.

Authors:  Hitoshi Yamahata; Hiroshi Tokimura; Kazuho Hirahara; Takeshi Ishii; Masanao Mori; Ryosuke Hanaya; Kazunori Arita
Journal:  J Neurol Surg B Skull Base       Date:  2014-05-02

10.  Stereotactic LINAC radiosurgery for the treatment of typical intracranial meningiomas. Efficacy and safety after a follow-up of over 12 years.

Authors:  Mustafa El-Khatib; Faycal El Majdoub; Stefan Hunsche; Mauritius Hoevels; Martin Kocher; Volker Sturm; Mohammad Maarouf
Journal:  Strahlenther Onkol       Date:  2015-08-08       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.